Document is current
Any future updates will be listed below
-
Authors
Erdle, Stephanie C.
Carr, Stuart
Chan, Edmond S.
Robertson, Kara
Watson, Wade
- License Information
-
More Information
Article History
Received: 24 July 2024
Accepted: 13 November 2024
First Online: 19 December 2024
Declarations
:
: Ethics approval and consent to participate are not applicable to this review article.
: Not applicable.
: Dr. Stephanie Erdle has received honoraria from La Roche Posay and ALK, and has received research support from Avir-Pharma and Pfizer. Dr. Stuart Carr has received consulting fees and honoraria for continuing education from Sanofi. He was a local principal investigator for a Ception-sponsored study of reslizumab, a biological therapeutic agent for eosinophilic esophagitis. Dr. Edmond Chan has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Miravo, Medexus, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma, AstraZeneca, ALK, Alladapt; was co-lead of the CSACI oral immunotherapy guidelines; is on the Executive of the CSACI (Canadian Society of Allergy and Clinical Immunology); is on the Executive of the CPS (Canadian Paediatric Society) Allergy Section; and is a member of the healthcare advisory board for Food Allergy Canada. Dr. Kara Robertson has received honoraria for continuing education from ALK, AstraZeneca, Medexus Pharmaceuticals and Sanofi. Dr. Wade Watson is medical advisor for Food Allergy Canada. None of the authors received any incentive or funding for the preparation or review of the manuscript.
: This article has been published as part of Allergy, Asthma & Clinical Immunology, Volume 20 Supplement 03, 2024: Practical Guide for Allergy and Immunology in Canada 2024. The full contents of the supplement are available at
